Crizotinib is an ALK (anaplastic lymphoma kinase) mutation-targeting agent employed in the management of ALK-positive non-small cell pulmonary carcinoma (NSCLC) and various other neoplastic disorders. The gene discussed is ALK; the disease is neoplastic disease or syndrome.